Fig. 2

Change in monthly MSMD over DBTP and ATP of the EM study in users of MSM at baseline. Baseline values are not adjusted analysis; DBTP results are presented as adjusted means and 95 % CIs utilizing a generalized linear mixed model which includes treatment, visit, treatment by visit interaction, stratification factors region and prior/current treatment with migraine prophylactic medication, and baseline value as covariates and assuming a first-order autoregressive covariance structure. P-values for pairwise comparisons are nominal p-values without multiplicity adjustment. ATP results are presented as mean ± SE. ‘All erenumab 70 mg’ in the ATP at Week 52 comprised patients with the following DBTP treatment assignments: placebo (n = 83), erenumab 70 mg (n = 73), erenumab 140 mg (n = 88). ‘All erenumab 140 mg’ in the ATP comprised patients with the following DBTP treatment assignments: placebo (n = 77), erenumab 70 mg (n = 77), erenumab 140 mg (n = 73). ATP, active treatment phase, CI, confidence interval; DBTP, double-blind treatment phase; EM, episodic migraine; M, Month; MSM, migraine-specific medication; MSMD, migraine-specific medication days; SE, standard error